tetano
Editor, Senior Moderator
Can J Infect Dis Med Microbiol. 2013 Spring;24(1):e7-e10.
Low seroconversion after one dose of AS03-adjuvanted H1N1 pandemic influenza vaccine in solid-organ transplant recipients.
Resende MR1, Husain S2, Gubbay J3, Singer L4, Cole E4, Renner EL4, Rotstein C2.
Author information
Abstract
in English, French
BACKGROUND:
Immunocompromised individuals are more susceptible to complications produced by influenza infection. As a result, solid-organ transplant (SOT) recipients were targeted as a priority group to receive AS03-adjuvanted H1N1 influenza vaccine during 2009.
OBJECTIVE:
To evaluate seroconversion after one dose of adjuvanted pandemic influenza H1N1 (pH1N1) vaccine in SOT recipients.
METHODS:
Adult SOT recipients were enrolled to receive one 3.75 μg dose of adjuvanted pH1N1 vaccine. Serological status was tested using a hemagglutination inhibition assay before and two and four weeks postvaccination.
RESULTS:
The five SOT recipients (one liver, two kidney and two lung transplants) had a median age of 50 years (range 36 to 53 years), and three were male, who were a median time of three years (range two months to 15 years) post-transplant. All patients were on a double or triple immunosuppressive regimen. The prevaccination pH1N1 titre was 1:10 in four patients and 1:40 in one patient. Seroprotection was observed only in one patient, with a rise in titre from 1:40 at baseline to 1:320 at both two and four weeks after vaccination. This lung transplant recipient had documented previous infection with pH1N1.
CONCLUSION:
Results of the present small study call into question whether one dose of adjuvanted pH1N1 vaccine can provide seroprotection in SOT recipients.
KEYWORDS:
H1N1, Immunogenicity, Influenza, Solid organ, Transplant, Vaccine
PMID:
24421799
[PubMed]
PMCID:
PMC3630030
[Available on 2014/3/1]
http://www.ncbi.nlm.nih.gov/pubmed/24421799
Low seroconversion after one dose of AS03-adjuvanted H1N1 pandemic influenza vaccine in solid-organ transplant recipients.
Resende MR1, Husain S2, Gubbay J3, Singer L4, Cole E4, Renner EL4, Rotstein C2.
Author information
Abstract
in English, French
BACKGROUND:
Immunocompromised individuals are more susceptible to complications produced by influenza infection. As a result, solid-organ transplant (SOT) recipients were targeted as a priority group to receive AS03-adjuvanted H1N1 influenza vaccine during 2009.
OBJECTIVE:
To evaluate seroconversion after one dose of adjuvanted pandemic influenza H1N1 (pH1N1) vaccine in SOT recipients.
METHODS:
Adult SOT recipients were enrolled to receive one 3.75 μg dose of adjuvanted pH1N1 vaccine. Serological status was tested using a hemagglutination inhibition assay before and two and four weeks postvaccination.
RESULTS:
The five SOT recipients (one liver, two kidney and two lung transplants) had a median age of 50 years (range 36 to 53 years), and three were male, who were a median time of three years (range two months to 15 years) post-transplant. All patients were on a double or triple immunosuppressive regimen. The prevaccination pH1N1 titre was 1:10 in four patients and 1:40 in one patient. Seroprotection was observed only in one patient, with a rise in titre from 1:40 at baseline to 1:320 at both two and four weeks after vaccination. This lung transplant recipient had documented previous infection with pH1N1.
CONCLUSION:
Results of the present small study call into question whether one dose of adjuvanted pH1N1 vaccine can provide seroprotection in SOT recipients.
KEYWORDS:
H1N1, Immunogenicity, Influenza, Solid organ, Transplant, Vaccine
PMID:
24421799
[PubMed]
PMCID:
PMC3630030
[Available on 2014/3/1]
http://www.ncbi.nlm.nih.gov/pubmed/24421799